SYRE

Spyre Therapeutics (SYRE)

About Spyre Therapeutics (SYRE)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Details

Daily high

$104.96

Daily low

$102.26

Price at open

$102.94

52 Week High

$108.14

52 Week Low

$14.50

Market cap

9.1B

Dividend yield

Volume

891,635

Avg. volume

797,076

P/E ratio

-47.54

Spyre Therapeutics News